Latest news and press releases about Edesa Biotech, Inc. (EDSA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate.
Price
| Price | $3.87 |
| Market Cap | $37M |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | 3.96 |
| EV / EBITDA | -2.46 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -124.21% |
| Return on Invested Capital | -166.02% |
| Return on Assets | -110.85% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BRTX · COCP · DWTX · ERNA · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of EDSA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks